Western blot diagnosis of vivax malaria with multiple stage-specific antigens of the parasite

Eui-Sun SON¹⁾, Tong Soo KIM²⁾ and Ho-Woo NAM^{1)*}

Department of Parasitology and Catholic Institute of Parasitic Diseases¹⁾, Catholic University of Korea, Seoul 137-701, Department of Medical Zoology²⁾, National Institute of Health, Seoul 122-201, Korea

Abstract: Western blot analysis was performed to diagnose vivax malaria using stage-specific recombinant antigens. Genomic DNA from the whole blood of a malaria patient was used as templates to amplify the coding regions for the antigenic domains of circumsporozoite protein (CSP-1), merozoite surface protein (MSP-1), apical merozoite antigen (AMA-1), serine repeat antigen (SERA), and exported antigen (EXP-1) of *Plasmodium vivax*. Each amplified DNA fragment was inserted into a pGEX-4T plasmid to induce the expression of GST fusion protein in *Escherichia coli* by IPTG. The bacterial cell extracts were separated on 10% SDS-PAGE followed by western blot analysis with patient sera which was confirmed by blood smear examination. When applied with patient sera, 147 (91.9%) out of 160 vivax malaria, 12 (92.3%) out of 13 falciparum malaria, and all 9 vivax/falciparum mixed malaria reacted with at least one antigen, while no reactions occurred with 20 normal uninfected sera. In the case of vivax malaria, CSP-1 reacted with 128 (80.0%) sera, MSP-1 with 102 (63.8%), AMA-1 with 128 (80.0%), SERA with 115 (71.9%), and EXP-1 with 89 (55.6%), respectively. We obtained higher detection rates when using 5 antigens (91.9%) rather than using each antigen solely (55.6 – 80%), a combination of 2 (76.3 – 87.5%), 3 (85.6 – 90.6%), or 4 antigens (89.4 – 91.3%). This method can be applied to serological diagnosis, mass screening in endemic regions, or safety test in transfusion of prevalent vivax malaria.

Key words: vivax malaria, western blot, multiple antigens, recombinant antigen, serodiagnosis

INTRODUCTION

Since 1993, when an indigenous case of *Plasmodium vivax* infection was reported (Chai et al., 1994), more than 10,000 cases of vivax

malaria have occurred in the south-west and near the demilitarized zone (DMZ) of Korea (Feighner et al., 1998; Lee et al., 1998; reviewed by Chai, 1999; Ree, 2000). The re-emergence of vivax malaria has been presumed to expand from the endemic regions in the north of DMZ mainly by the changes in the vector environments, although there are no information available on the endemic status in the north. Unique clinical features of the prolonged incubation period and genetic approaches (Kho et al., 1999; Lim et al., 2000) demonstrated that the prevalent strain had very similar characteristics to the North

• Received 3 April 2001, accepted after revision 16 May 2001.

• This study was supported by a grant (HMP-99-M-04-0002) of 1999, Good Health R&D Project, Ministry of Health and Welfare, Republic of Korea.

*Corresponding author (e-mail: howoo@cmc.cuk.ac.kr)

Korean strain described by Shute et al. (1977).

Microscopic examinations of Giemsa-stained thick and thin blood smears (BS) have been the diagnostic method of choice (Warhurst and Williams, 1996). However, there are two limitations when detecting vivax malaria: one is caused by the biology of vivax malaria and the other by the examiner. It is not possible to observe parasites by BS during the irregular prolonged incubation periods of vivax malaria in the temperate climate regions (Krotoski, 1985) of which the incubation periods vary from 153 to 452 days before the onset of malarial symptoms in the Korean cases (Lee et al., 1998). And the other limitation of BS includes the lack of well-trained personnel and the length of time required for the examination, especially when parasitemia is as low as those in *P. vivax* infections.

Various detection methods have been developed to overcome these limitations such as antigen- (Shiff et al., 1993; Dietze et al., 1995) and nucleic acid-based detections (Barker et al., 1992; Li et al., 1995) of falciparum malaria. Antibody-based detection methods such as indirect haemagglutination test (WHO, 1988), indirect fluorescent antibody test (Mendis et al., 1987), and ELISA tests (Demedts et al., 1987; Del Giudice et al., 1987) have also been established. Up until now, western blot (WB) has not been performed as a method of serological diagnosis of malaria. In an attempt to establish a WB diagnosis of vivax malaria, we carried out WB with patients' sera against multiple recombinant antigens selected as stage-

specific antigens to vivax malaria.

MATERIALS AND METHODS

Examination of blood smear and plasma collection

Thin blood films were stained with Diff-Quick solution (International Reagents Corp., Kobe, Japan) and examined under oil-immersion (100X) for 10 fields. Plasma was collected after centrifugation of the whole blood at 12,000 rpm and frozen at -70°C until use. With this method, 160 cases of *P. vivax* infections were diagnosed. And 13 additional cases of *P. falciparum* infections and 9 additional cases of *P. vivax/P. falciparum* mixed infections from endemic African or southeast Asian nations were also evaluated.

Polymerase chain reaction (PCR)

The DNA was extracted from the whole blood (200 µl) of a vivax malaria patient using a QIAamp DNA mini kit (QIAGEN, Valencia, CA) according to the manufacturer's protocol. Primers were synthesized as in Table 1 on the coding regions for the antigenic domains of circumsporozoite protein (CSP-1, GeneBank accession No. M34697), merozoite surface protein (MSP-1, M60807), apical merozoite antigen (AMA-1, AF063138), serine repeat antigen (SERA, AF052747), and exported antigen (EXP-1, X05074) of *Plasmodium vivax*. Denaturing and extension temperatures used for PCR were 95°C for 1 min and 72°C for 2 min for 30 cycles. The annealing temperature of each reaction was described in Table 1.

Table 1. Primer sets designed for the amplification of antigenic domains of each protein

Genes	Name of primers	Sequences	Annealing Temp.(°C)	References
CSP-1	CSPF	5' -cac gta gga caa agt gct agc-3'	52	Arnot et al., 1990
	CSPR	5' -tac act gca tgg agt cca ttc-3'		
MSP-1	MSPF	5' -cta cta ctt gat ggt cct caa-3'	56	Del Portillo et al., 1991
	MSPR	5' -ttg tga cat gcg taa gcg gat-3'		
AMA-1	AMAF	5' -atg aat aaa ata tac tac ata-3'	55	Rogers et al., 1999
	AMAR	5' -ata ctg agt tgg ttg atc tga-3'		
SERA	SERAF	5' -aga ggg gtg cac aac atg tgc-3'	55	Gor et al., 1998
	SERAR	5' -tca cac ata gca gaa gta gca-3'		
EXP-1	EXPF	5' -gaa aaa aca aac aaa gaa-3'	54	Simmons et al., 1987
	EXPR	5' -tac agc tgt tta gtg ttc agg-3'		

Production of recombinant GST fusion antigens

The amplified DNA fragments of CSP-1, MSP-1, AMA-1, SERA, and EXP-1 were cloned into pGEM-T Easy vector (Promega, Madison, WI) to subclone in pGEX-4T vector (Amersham Pharmacia Biotech, Uppsala, Sweden). An in-frame insertion of each plasmid was confirmed by sequencing the vectors with T7 and SP6 sequencing primers. Each protein was expressed as GST fusion proteins in *Escherichia coli* (HB101 strain) by the isopropyl- β -D-thiogalactoside (IPTG) induction for 3 hr at 30°C.

Western blot

Western blot was performed by the method of Towbin et al. (1979). The whole bacterial cell extracts were separated in 10% SDS-PAGE gels and transferred onto nitrocellulose sheets (NC, Schleicher and Shuell, Keene, NH). NC membrane, blocked with 5% skim milk in PBS/0.05% Tween-20, was incubated with serum of 1:500 dilution followed by a subsequent incubation with 1:2,000 diluted HRP-conjugated goat anti-human IgG antibody (Cappel, Costa Mesa, CA). The membrane was soaked in enhanced chemiluminescence (ECL) solution (Intron, Daejon, Korea) for 1 min and exposed to an X-ray film (Konica, Tokyo, Japan). Positive reaction was determined by at least one or more bindings with specific antigens, and the arbitrary band intensity was measured after scanning the films.

RESULTS

Amplification of gene fragments by PCR and expression as GST fusion proteins

The coding regions for the antigenic domains of CSP-1, MSP-1, AMA-1, SERA, and EXP-1 of *P. vivax* were amplified by PCR as 774, 456, 894, 867, and 423 bp as shown in Fig. 1. Amplified DNA fragments were cloned into pGEM-T Easy vector to subclone in pGEX-4T vector with the restriction of Eco RI. In-frame insertion of each plasmid was confirmed by sequencing the vector with T7 and SP6 sequencing primers. Each protein was expressed as the GST fusion protein in HB101

Fig. 1. PCR-amplified coding gene fragments of *Plasmodium vivax* separated in 1.2% agarose gel.

Fig. 2. Confirmation of GST fusion proteins by western blot with anti-GST antibody.

bacteria by the IPTG induction with the molecular mass of 58 kDa for CSP-1, 48 kDa for MSP-1, 60 kDa for AMA-1, 56 kDa for SERA, and 42 kDa for EXP-1, respectively, by the GST detection as marked with asterisks (*) in Fig. 2.

Detection of GST fusion antigens by patients' sera

All GST fusion proteins were antigenic sufficiently against sera of malaria patients without binding to GST only. When applied with patients' sera, 147 (91.9%) out of 160 vivax malaria, 12 (92.3%) out of 13 falciparum malaria, and all 9 vivax/falciparum mixed malaria reacted with at least one antigen, while no reactions were observed with 20 normal uninfected sera (Table 2).

Table 2. Seroreactivity of each antigen on the blood smear positive sera

Antigen	<i>P. vivax</i>	<i>P. falciparum</i>	<i>Pv/Pf</i> mixed	Negative
CSP-1	128/160 (80.0)	8/13 (61.5)	1/9 (11.1)	0/20
MSP-1	102/160 (63.8)	8/13 (61.5)	6/9 (66.7)	0/20
AMA-1	128/160 (80.0)	8/13 (61.5)	2/9 (22.2)	0/20
SERA	115/160 (71.9)	6/13 (46.2)	4/9 (44.4)	0/20
EXP-1	89/160 (55.9)	12/13 (92.3)	9/9 (100.0)	0/20
Total	147/160 (91.9)	12/13 (92.3)	9/9 (100.0)	0/20

Table 3. Positive detection of vivax malaria by the number of antigens used in western blot

1 ^{a)} Ag NP ^{b)} (%)	2 Ag NP (%)	3 Ag NP (%)	4 Ag NP (%)	5 Ag NP (%)
C 128 (80.0)	CM 138 (86.3)	CMA 140 (87.5)	CMAS 143 (89.4)	CMASE 147 (91.9)
M 102 (63.8)	CA 132 (82.5)	CMS 142 (88.8)	CMAE 145 (90.6)	
A 128 (80.0)	CS 135 (84.4)	CME 144 (90.0)	MASE 146 (91.3)	
S 115 (71.9)	CE 138 (86.3)	CAS 137 (85.6)		
E 89 (55.6)	MA 138 (86.3)	CAE 141 (88.1)		
	MS 130 (81.3)	CSE 143 (89.4)		
	ME 122 (76.3)	MAS 142 (88.8)		
	AS 136 (85.0)	MAE 145 (90.6)		
	AE 140 (87.5)	ASE 143 (89.4)		
	SE 134 (83.8)			

^{a)}No. of Ag used

^{b)}NP: number of positive among 160 tested

C, CSP-1; M, MSP-1; A, AMA-1; S, SERA; and E, EXP-1

In cases of vivax malaria, CSP-1 reacted with 128 (80.0%) sera, MSP-1 with 102 (63.8%), AMA-1 with 128 (80.0%), SERA with 115 (71.9%), and EXP-1 with 89 (55.6%), respectively. Among the 147 vivax malaria positive reactions, 10 sera (6.8%) reacted with only one antigen, 15 sera (10.2%) with two antigens, 22 sera (15.0%) with three antigens, 43 sera (29.3%) with four antigens, and 57 sera (38.8%) with all five antigens used. As shown in Table 3, higher detection rates were obtained when using 5 antigens (91.9%) rather than using each antigen solely (55.6 – 80%), a combination of 2 (76.3 – 87.5%), 3 (85.6 – 90.6%), or 4 antigens (89.4 – 91.3%).

And in cases of falciparum and vivax/falciparum mixed malaria, EXP-1 reacted strongly with sera in all western blot positives.

DISCUSSION

The GST fusion recombinant proteins coding the antigenic domains of CSP-1, MSP-1, AMA-1, SERA, and EXP-1 of *P. vivax* were analyzed in western blot with patients' sera to establish a diagnostic method. Each antigen was highly specific and reactive to some sera but the sensitivity was not enough when used solely, which resulted from the complexity in humoral immunity of vivax malaria (Krotoski, 1985). However, when four or five antigens were combined as detection antigens, positive reactions were identified as above 90%. There is space to be improved, this western blot with multiple antigens can be used as an antibody-based detection method.

Even though all samples were confirmed to be infected with the parasite by blood smear examination, sera of 13 cases (8.1%) in 160 vivax malaria and 1 case (among 13 cases) of

falciparum malaria did not react in western blot. These vivax cases were presumed to be immediate onsets according to the due course without prolonged pre-erythrocytic stage, which might occur before the production of antibodies to the parasite.

And most imported malaria cases were caused by *P. falciparum* infection in Korea. Most of the travelers to the tropic and sub-tropic endemic regions have been guided to have prophylaxis against malaria, which results in the prevention in most travelers regardless of mosquito biting. But in some cases, not protected completely, malarial symptoms were suppressed merely during stay in the endemic region. Antibodies preformed before the onset of symptoms by recrudescence were detected in western blot in most imported cases except for 1 case in this study.

Western blot diagnosis with circumsporozoite and hypnozoite stage antigens will play critical role in the diagnosis of prolonged incubation period, especially in vivax malaria. And with merozoite antigens in addition to the antigens of exo-erythrocytic stages may provide useful information on the clinical procedure of vivax malaria. It can also be used in the epidemiological screening and safety detection of blood bank donors. Army soldiers have served as a large pool of blood donors in Korea. But the overlap of endemic regions and garrison camps (Kho et al., 1999) makes the blood supply to be perilous. Repeated mass screening methods may be helpful to select healthy donors under this situation, we propose a seasonal screening during winter when the mosquitoes not active.

REFERENCES

Arnot DE, Stewart MJ, Barnwell JW (1990) Antigenic diversity in Thai *Plasmodium vivax* circumsporozoite proteins. *Mol Biochem Parasitol* **43**: 147-149.

Barker RH, Banchongaksorn T, Courval JM, Suwonkerd W, Rimwuntragoon K, Wirth DF (1992) A simple method to detect *Plasmodium falciparum* directly from blood samples using the polymerase chain reaction. *Am J Trop Med Hyg* **46**: 416-426.

Chai IH, Lim GI, Yoon SN, Oh WI, Kim SJ, Chai JY (1994) Occurrence of tertian malaria in a male patient who has never been abroad. *Korean J Parasitol* **32**: 195-200. (in Korean)

Chai JY (1999) Re-emerging *Plasmodium vivax* malaria in the Republic of Korea. *Korean J Parasitol* **37**: 129-143.

Del Giudice G, Verdini AS, Pinori M, et al. (1987) Detection of human antibodies against *Plasmodium falciparum* sporozoites using synthetic peptides. *J Clin Microbiol* **25**: 91-96.

Del Portillo HA, Longacre S, Khouri E, David PH (1991) Primary structure of the merozoite surface antigen 1 of *Plasmodium vivax* reveals sequences conserved between different *Plasmodium* species. *Proc Natl Acad Sci USA* **88**: 4030-4034.

Demedts P, Vermuelen-Van Overmeier C, Wery M (1987) Simultaneous use of *Plasmodium falciparum* crude antigen and red blood cell antigen in the enzyme-linked immunosorbent assay for malaria. *Am J Trop Med Hyg* **36**: 257-263.

Dietze R, Perkins M, Boulous M, Luz F, Reller B, Corey GR (1995) The diagnosis of *Plasmodium falciparum* infection using a new antigen detection system. *Am J Trop Med Hyg* **52**: 45-49.

Feighner BH, Pak SI, Novakoski WL, Kelsey LL, Strickman D. (1998) Reemergence of *Plasmodium vivax* malaria in the Republic of Korea. *Emerg Infect Dis* **4**: 295-297.

Gor DO, Li AC, Wiser MF, Rosenthal PJ (1998) Plasmodial serine repeat antigen homologues with properties of schizont cysteine proteases. *Mol Biochem Parasitol* **95**: 153-158.

Kho WK, Jang JY, Hong ST, Lee HW, Lee WJ, Lee JS (1999) Border malaria infection in the Republic of Korea. *Korean J Parasitol* **37**: 71-76.

Krotoski WA (1985) Discovery of hypnozoite and a new theory of malarial relapse. *Trans Roy Soc Trop Med Hyg* **79**: 1-11.

Lim CS, Kim SH, Kwon SI, Song JW, Song KJ, Lee KN (2000) Analysis of *Plasmodium vivax* merozoite surface protein-1 gene sequences from resurgent Korean isolates. *Am J Trop Med Hyg* **62**: 261-265.

Lee JS, Kho WG, Lee HW, Seo M, Lee WJ (1998) Current status of vivax malaria among civilians in Korea. *Korean J Parasitol* **36**: 241-248.

Li J, Wirtz RA, McConkey GA, et al. (1995)

- Plasmodium*: genus-conserved primers for species identification and quantification. *Exp Parasitol* **81**: 182-190.
- Mendis KN, Munesinghe YD, de Silva YN, Keragalla I, Carter R (1987) Malaria transmission-blocking immunity induced by natural infections of *Plasmodium vivax* in humans. *Infect Immun* **55**: 369-372.
- Ree HI (2000) Unstable vivax malaria in Korea. *Korean J Parasitol* **38**: 119-138.
- Rogers WO, Gowda K, Hoffman SL (1999) Construction and immunogenicity of DNA vaccine plasmids encoding four *Plasmodium vivax* candidate vaccine antigens. *Vaccine* **17**: 3136-3144.
- Shiff CJ, Premji Z, Minjas JN (1993) The rapid manual ParaSight-F test. A new diagnostic tool for *Plasmodium falciparum* infection. *Trans Roy Soc Trop Med Hyg* **87**: 646-648.
- Shute PG, Lupascu G, Branzei P, et al. (1977) A strain of *Plasmodium vivax* characterized by prolonged incubation: the effect of numbers of sporozoites on the length of the prepatent period. *Trans Roy Soc Trop Med Hyg* **70**: 474-481.
- Simmons D, Woollett G, Bergin-Cartwright M, Kay D, Scaife J (1987) A malaria protein exported into a new compartment within the host erythrocyte. *EMBO J* **6**: 485-491.
- Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci USA* **76**: 4350-4354.
- Warhurst DC, Williams JE (1996) Laboratory diagnosis of malaria. *J Clin Pathol* **49**: 533-538.
- World Health Organization (1988) Malaria diagnosis: memorandum from a WHO meeting. *Bull World Health Organ* **66**: 575-594.